A 68-year-old man without previous comorbidities presented to the emergency department with complaints of palpitations and giddiness. On examination, his pulse rate was 92 beats per minute, and his ...

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced the appointment of. Mr. Sandoval’s appointment comes as Milestone launches CARDAMYST™ (etripamil) nasal spray, the first and only approved ...

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced the appointment of David Sandoval as General Counsel and Chief Compliance ...

TCTMD spoke with Lior Jankelson, MD, PhD (NYU Langone Health, New York, NY), an electrophysiologist who leads the AI/machine ...

Brazil: Stopping oral anticoagulants (OACs) after atrial fibrillation ablation does not significantly change overall thromboembolic (TE) event rates and is associated with a reduction in ...

OPPO's new Watch S features industry-leading slim design, advanced fitness tracking and flagship health analysis ...

A female doctor defied odds, performing 30 minutes of continuous CPR on a collapsed patient in cardiac arrest. Her exceptional endurance and adherence to advanced life support protocols restored the ...

I Tested the ‘Thermometer of the Future,’ and I Think This Is Its Ideal User ...

FDA drug alerts in pulmonology, including drug approvals/warnings, vaccine approvals, medical device recalls/updates, and ...

Detailed price information for Milestone Pharmaceuticals Inc (MIST-Q) from The Globe and Mail including charting and trades.

The Option awards are subject to the award holder’s continuous service through each vesting date and to the terms and conditions of the Plan and its standard forms of grant agreements thereunder.

Atrial fibrillation, a common heart rhythm disorder, can be dangerous. Heart surgeon explains its risk factors, treatments, and procedures.